EUVIMEDEUVIMED entdecken
FallberichtOpen Access · CC BY 4.0

Successful Use of Recombinant Tissue Plasminogen Activator in an Extremely Low Birth Weight Premature Infant for the Resolution of Multiple Thrombi

Kartik Mody, Christine Wade iD, Becky Micetic iD, Myleanna Vernon, Natalie Wade iD

American Journal of Perinatology Reports · 01.01.2026 · 16 (01) · e1-e6

DOI: 10.1055/a-2780-3344 ↗

Kurz gefasst

Fallbericht in der Zeitschrift American Journal of Perinatology Reports, erschienen am 01.01.2026. Verfasst von Kartik Mody und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neonatology, Pediatrix/Arizona Neonatology, Phoenix, Arizona, United States. Die Arbeit nennt 41 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Introduction

The literature is limited regarding the use of recombinant tissue plasminogen activator (r-tPA) in premature infants. We describe the use of r-tPA to treat life-threatening intra- and extracardiac thrombi in a very low birth weight patient born at 23 weeks of gestational age. Case Report An extremely premature infant was diagnosed with multiple thrombi at 4 weeks of age. The acute phase of treatment was managed with an infusion of r-tPA followed by unfractionated heparin, then low-molecular-weight heparin for continued anticoagulation. The patient did not experience any side effects associated with the therapies and was discharged home.

Conclusion

Thrombotic events in neonates, though rare, are being increasingly identified due to improved survival of premature infants, enhanced diagnostic modalities, and the widespread use of central venous catheters. Heparin remains the standard of care in neonates for anticoagulation. Thrombolytic therapy with agents such as r-tPA, though less frequently employed, may be lifesaving in certain instances, such as the one presented in this case report. Key Points r-tPA use in premature infants may resolve thrombi. r-tPA can be used safely in extremely low birth weight infants. Heparin/r-tPA is used to treat multiple cardiac thrombi.

Schlagwörter

Stichwörter der Autor:innen

extremely prematureheparininfantlow-molecular-weightrecombinant tissue plasminogen activatorthrombolytic therapythrombosis

Autor:innen und Institutionen

  • Department of Neonatology, Pediatrix/Arizona Neonatology, Phoenix, Arizona, United States.
  • Neonatal Intensive Care Unit, Banner - University Medical Center Phoenix, Phoenix, Arizona, United States.
  • College of Medicine, University of Arizona College of Medicine, Phoenix, Arizona, United States.
  • Department of Pediatrics, Creighton University School of Medicine, Phoenix, Arizona, United States.

ORCID-Profile: Christine Wade, Becky Micetic, Natalie Wade

Zitieren

APA

Mody, K., Wade, C., Micetic, B., Vernon, M., & Wade, N. (2026). Successful Use of Recombinant Tissue Plasminogen Activator in an Extremely Low Birth Weight Premature Infant for the Resolution of Multiple Thrombi. American Journal of Perinatology Reports, 16(01), e1-e6. https://doi.org/10.1055/a-2780-3344

Vancouver

Mody K, Wade C, Micetic B, Vernon M, Wade N. Successful Use of Recombinant Tissue Plasminogen Activator in an Extremely Low Birth Weight Premature Infant for the Resolution of Multiple Thrombi. American Journal of Perinatology Reports. 2026;16(01):e1-e6. doi:10.1055/a-2780-3344

BibTeX
@article{Mody2026,
  author = {Mody, Kartik and Wade, Christine and Micetic, Becky and Vernon, Myleanna and Wade, Natalie},
  title = {Successful Use of Recombinant Tissue Plasminogen Activator in an Extremely Low Birth Weight Premature Infant for the Resolution of Multiple Thrombi},
  journal = {American Journal of Perinatology Reports},
  year = {2026},
  volume = {16},
  number = {01},
  pages = {e1--e6},
  doi = {10.1055/a-2780-3344}
}
Kostenlos starten →